# Comorbidity Matrix

## Purpose
This reference document provides guidance for managing patients with multiple concurrent conditions in remote monitoring programs. It identifies overlapping monitoring parameters, shared devices, and special considerations for common comorbidity combinations.

---

## Common Comorbidity Patterns

Based on Carepath SOP documentation, the following comorbidity combinations are frequently encountered:

| Primary Condition | Common Comorbidities | Prevalence Note |
|-------------------|---------------------|-----------------|
| **CHF** | Diabetes, Hypertension, COPD | Very common - heart failure patients often have metabolic and respiratory comorbidities |
| **COPD** | CHF, Hypertension, Diabetes | Common - shared risk factors (smoking, age, hypertension) |
| **Pneumonia** | COPD, Diabetes, Hypertension | Common - comorbidities increase pneumonia risk and severity |
| **Hypertension** | Diabetes, Hyperlipidemia, CHF | Very common - HTN is major risk factor for cardiac disease |
| **Diabetes** | Hypertension, COPD, Hyperlipidemia | Very common - metabolic syndrome constellation |
| **DVT** | CHF, COPD | Moderate - immobility and cardiac dysfunction increase VTE risk |
| **COVID-19** | Any of above | Universal - COVID outcomes worse with any comorbidity |

---

## Comorbidity Combination Matrix

### CHF + Diabetes

#### Overlapping Monitoring
- **Shared concern**: Volume status affects glucose control, diabetes increases CHF risk
- **Weight monitoring**: Critical for both conditions
  - CHF: Fluid retention detection (>0.9kg/day)
  - Diabetes: Long-term weight management for glycemic control
- **BP monitoring**: Essential for both
  - CHF: Monitor for hypotension (over-diuresis)
  - Diabetes: HTN common comorbidity, target <130/80
- **Activity tolerance**: Both conditions cause fatigue

#### Shared Devices
- **Weight scale**: Daily for CHF (acute), regular for Diabetes
- **BP cuff**: Twice daily for both conditions
- **Glucometer**: Q6hrs for Diabetes

#### Special Considerations
- **Diuretics + Hyperglycemia**: Loop diuretics can worsen glucose control
  - Monitor glucose more closely when adjusting diuretics
- **SGLT2 inhibitors**: Benefit both CHF and Diabetes
  - Reduce HF hospitalizations + improve glycemic control
  - Monitor for euglycemic DKA (rare)
- **Diabetic nephropathy**: Affects diuretic response and CHF management
  - May require higher diuretic doses
  - Monitor renal function closely

#### Alert Prioritization
1. **Weight gain + hyperglycemia**: Distinguish CHF exacerbation vs poor diabetes control
   - CHF: Rapid weight gain (days), SOB, edema
   - Diabetes: Gradual weight changes, polyuria, polydipsia
2. **Hypoglycemia + diuretics**: Volume depletion reduces glucose counterregulation

---

### COPD + CHF

#### Overlapping Monitoring
- **Dyspnea**: Both conditions cause shortness of breath
  - COPD: Gradual onset, chronic, improves with bronchodilators
  - CHF: Acute onset, orthopnea, improves with diuretics
- **SpO2**: Critical for both
  - COPD: Baseline may be lower (88-92%)
  - CHF: Should be >92%; <92% suggests pulmonary edema
- **Respiratory Rate**: Elevated in both exacerbations

#### Shared Devices
- **Everion armband OR VitalPatch**: Continuous HR, RR, SpO2, activity
- **BP cuff**: Monitor for both cardiac and pulmonary hypertension effects
- **Pulse oximeter**: Frequent spot checks

#### Special Considerations
- **Beta-blockers**: Essential for CHF, may worsen COPD
  - Use cardioselective beta-blockers (metoprolol, bisoprolol)
  - Do NOT withhold beta-blockers in COPD+CHF patients
- **Diuretics**: Help CHF, may thicken COPD secretions
  - Monitor sputum production and hydration
- **Oxygen therapy**: Complex in COPD+CHF
  - COPD: Risk of CO2 retention if O2 too high (target SpO2 88-92%)
  - CHF: Need adequate oxygenation (target SpO2 >92%)
  - **Compromise target**: SpO2 92-94%

#### Alert Prioritization
1. **Acute SOB**: Differentiate COPD exacerbation vs CHF exacerbation
   - COPD: Purulent sputum, wheezing, fever
   - CHF: Weight gain, orthopnea, edema, crackles
2. **Both conditions**: Treat both simultaneously if ambiguous

#### Diagnostic Clues
- **BNP/NT-proBNP**: Elevated in CHF, normal in pure COPD exacerbation
- **Sputum color**: Purulent suggests COPD exacerbation
- **Weight trend**: Rapid gain suggests CHF component

---

### Diabetes + Hypertension

#### Overlapping Monitoring
- **BP control**: More aggressive targets in diabetes
  - Target <130/80 mmHg (vs <140/90 in HTN alone)
- **Renal function**: Both conditions affect kidneys
  - Monitor creatinine, eGFR
  - Screen for diabetic nephropathy (albuminuria)
- **Cardiovascular risk**: Shared end-organ damage

#### Shared Devices
- **BP cuff**: Twice daily
- **Glucometer**: Q6hrs (Diabetes) + PRN if hypo/hypertensive symptoms

#### Special Considerations
- **ACE inhibitors / ARBs**: First-line for both conditions
  - Renoprotective in diabetic nephropathy
  - Reduce CV events
  - Monitor potassium (risk of hyperkalemia)
- **Thiazide diuretics**: Effective for HTN, may worsen glucose
  - Use low-dose to minimize hyperglycemia
  - Monitor HbA1c trends
- **Hypoglycemia + Hypotension**: Overlapping symptoms
  - Dizziness could be either condition
  - Check both glucose AND BP when symptomatic

#### Alert Prioritization
1. **Dizziness**: Check glucose first (faster), then BP
2. **Vision changes**: Could be hypertensive retinopathy OR diabetic retinopathy
   - Ophthalmology referral for either

---

### COPD + Diabetes

#### Overlapping Monitoring
- **Infection risk**: Both increase susceptibility
- **Steroid use**: COPD exacerbations require steroids, which worsen glucose
- **Activity limitation**: Both cause fatigue

#### Shared Devices
- **Everion armband**: HR, RR, SpO2, activity for COPD
- **BP cuff**: Monitor for HTN (common comorbidity with both)
- **Glucometer**: Essential, especially during COPD exacerbations

#### Special Considerations
- **Corticosteroids**: Mainstay of COPD exacerbation, worsen diabetes
  - **Plan ahead**: Increase glucose monitoring frequency (Q4hrs) when starting steroids
  - May need temporary insulin even if usually diet/oral agent controlled
  - Monitor for steroid-induced hyperglycemia (can reach >20 mmol/L)
- **Infection**: Hyperglycemia increases pneumonia/COPD exacerbation risk
  - Tight glucose control (target <10 mmol/L) during respiratory infections
- **Inhaled steroids**: Minimal systemic absorption, less impact on glucose

#### Alert Prioritization
1. **Fever + hyperglycemia + respiratory symptoms**: Treat as COPD exacerbation with diabetic complication
2. **Hypoglycemia during exacerbation**: Decreased oral intake common

---

### CHF + Hypertension

#### Overlapping Monitoring
- **BP control**: Critical for CHF management
  - Target systolic <130 mmHg
  - Avoid hypotension (<90 systolic) from over-treatment
- **Volume status**: Both affected by BP medications

#### Shared Devices
- **VitalPatch**: Continuous HR, BP trends
- **BP cuff**: Multiple daily readings
- **Weight scale**: Daily for CHF, regular for medication monitoring

#### Special Considerations
- **ACE inhibitors / ARBs + Diuretics**: Cornerstone therapy for both
  - Risk of hypotension if over-diuresed
  - Monitor orthostatic vitals
- **Beta-blockers**: Essential for CHF, also lower BP
  - May need to reduce other antihypertensives when initiating
- **Hypertensive heart disease**: HTN causes CHF
  - Chronic HTN → LV hypertrophy → diastolic dysfunction → HFpEF

#### Alert Prioritization
1. **Hypotension + dizziness**: Hold diuretics and antihypertensives, assess volume status
2. **Hypertensive urgency in CHF patient**: Balance BP lowering with perfusion needs

---

### Pneumonia + COPD

#### Overlapping Monitoring
- **Respiratory symptoms**: Very similar presentations
- **SpO2**: Critical for both
- **Fever**: Distinguishes bacterial pneumonia from COPD exacerbation

#### Shared Devices
- **Everion armband**: Continuous respiratory monitoring
- **Thermometer**: Critical to detect fever (pneumonia) vs afebrile (COPD alone)
- **Pulse oximeter**: Frequent monitoring

#### Special Considerations
- **Antibiotic choice**: Must cover typical CAP pathogens + common COPD pathogens
  - Often use broader spectrum (fluoroquinolone, beta-lactam + macrolide)
- **Steroids**: Standard for COPD exacerbation, also reduce pneumonia mortality in severe cases
- **Bronchodilators**: Benefit both conditions

#### Alert Prioritization
1. **Fever + purulent sputum + infiltrate**: Pneumonia + COPD exacerbation (treat both)
2. **Persistent fever**: Suggests pneumonia predominates (vs COPD alone)

---

### Diabetes + Hyperlipidemia

#### Overlapping Monitoring
- **Cardiovascular risk**: Both increase atherosclerotic disease
- **Weight management**: Important for both
- **Diet**: Central to management of both

#### Shared Devices
- **Glucometer**: Daily for Diabetes
- **BP cuff**: Monitor for HTN (often concurrent)
- **Weight scale**: Regular monitoring for both conditions

#### Special Considerations
- **Statins**: First-line for hyperlipidemia, mandatory in diabetes
  - All diabetics age 40-75 should be on statin
  - Monitor for statin-induced hyperglycemia (small effect)
- **Fibrates**: Lower triglycerides, useful in diabetic dyslipidemia
  - Can be combined with statins (watch for myopathy)
- **Metabolic syndrome**: Often coexist with HTN and obesity

---

### DVT + CHF

#### Overlapping Monitoring
- **Lower extremity edema**: Difficult to distinguish DVT vs CHF
- **SOB**: PE symptoms overlap with CHF exacerbation
- **Weight gain**: CHF fluid retention vs DVT immobility

#### Shared Devices
- **VitalPatch**: Continuous monitoring for both conditions
- **Pulse oximeter**: Critical - PE causes hypoxia like CHF
- **BP cuff**: Monitor both conditions

#### Special Considerations
- **Anticoagulation in CHF**: Benefits (reduce stroke in AFib) vs risks (bleeding)
- **Diuretics + anticoagulation**: Hemoconcentration may increase VTE risk
  - Balance diuresis with adequate hydration
- **PE vs CHF exacerbation**: Very difficult to distinguish
  - Both cause acute SOB, tachycardia, hypoxia
  - **D-dimer not helpful** (elevated in CHF)
  - **May need CT PE protocol** if clinical deterioration

#### Alert Prioritization
1. **Acute SOB in DVT+CHF patient**: Always consider PE
2. **Unilateral leg swelling**: More likely DVT than CHF (which is bilateral)

---

### COVID-19 + Any Comorbidity

#### Universal Considerations
- **All comorbidities increase COVID severity**
- **Baseline disease may worsen** during COVID infection
- **Medications may interact** with COVID therapies

#### Specific Combinations

**COVID + CHF**:
- COVID can precipitate CHF exacerbation (myocardial injury, cytokine storm)
- Monitor daily weights, NT-proBNP
- Prone positioning may be challenging

**COVID + COPD**:
- Higher risk of severe disease and mortality
- Difficult to distinguish COVID pneumonia from COPD exacerbation
- Consider both diagnoses, treat empirically

**COVID + Diabetes**:
- Hyperglycemia worsens COVID outcomes
- COVID stress response causes hyperglycemia
- Increase glucose monitoring frequency
- Consider Paxlovid (but check drug interactions)

**COVID + Hypertension**:
- ACE2 receptor involvement (COVID entry point)
- DO NOT stop ACE inhibitors/ARBs
- Monitor BP (may be labile during acute illness)

**COVID + DVT**:
- COVID is hypercoagulable state
- Increased VTE risk
- May need prophylactic anticoagulation even without confirmed DVT

---

## Multi-Comorbidity Approach

### 3+ Conditions

**Priority Hierarchy** (address in this order):
1. **Acute life-threatening**: PE, ACS, septic shock, severe hypoglycemia
2. **Acute exacerbations**: CHF decompensation, COPD exacerbation, DKA
3. **Chronic management**: HTN control, diabetes optimization, lipid management

### Device Consolidation

For patients with multiple conditions, minimize device burden:
- **Use VitalPatch or Everion** (covers HR, RR, SpO2, temp) instead of separate devices
- **Single BP cuff** serves CHF, HTN, Diabetes monitoring needs
- **Add condition-specific devices** only as needed (glucometer for Diabetes, scale for CHF)

### Medication Review

**Polypharmacy risks**:
- **Drug-drug interactions**: Increased with >5 medications
- **Adherence challenges**: Simplified regimens improve compliance
- **Side effect overlap**: Dizziness (BP meds + hypoglycemia), fatigue (beta-blockers + anemia)

**Beneficial overlaps**:
- **ACE inhibitors / ARBs**: CHF + HTN + Diabetes (triple benefit)
- **Beta-blockers**: CHF + HTN + CAD (triple benefit)
- **Statins**: Diabetes + Hyperlipidemia + HTN (CV protection)
- **SGLT2 inhibitors**: Diabetes + CHF (dual benefit)

---

## Clinical Decision Support

### Symptom Overlap Resolution

| Symptom | Possible Causes (Comorbidities) | Diagnostic Approach |
|---------|--------------------------------|---------------------|
| **Dyspnea** | CHF, COPD, Pneumonia, PE, COVID | Check: Weight (CHF), SpO2 (all), sputum (COPD/Pneumonia), D-dimer (PE), COVID test |
| **Edema** | CHF, DVT, Nephrotic syndrome | Unilateral (DVT) vs Bilateral (CHF, renal), check weight trend |
| **Dizziness** | Hypoglycemia, Hypotension, Anemia | Check: Glucose first, then BP, then Hgb |
| **Fatigue** | CHF, Diabetes, COPD, Anemia, Depression | Gradual (chronic) vs Acute onset, check activity tolerance, labs |
| **Chest pain** | ACS, PE, COVID, HTN urgency | ECG, troponin, D-dimer, COVID test, BP |

### Alert Triage with Comorbidities

**When multiple alerts fire simultaneously:**
1. **Life-threatening first**: SpO2 <88%, SBP <90, Glucose <2.8 mmol/L
2. **Assess most likely primary cause** based on symptom pattern
3. **Treat conservatively** (address both if uncertain)
4. **Re-assess after initial intervention**

---

## Documentation Template for Comorbid Patients

```
Patient: [ID]
Primary Condition: [e.g., CHF Acute]
Comorbidities: [e.g., Diabetes Type 2, Hypertension]

Today's Assessment:
- CHF: Weight [X]kg (Δ [+/-] kg), SOB [level], Edema [Y/N]
- Diabetes: Glucose range [X-Y] mmol/L, Hypo episodes [#], Adherence [Y/N]
- HTN: BP range [X-Y] mmHg, Symptoms [list]

Comorbidity Interactions:
- [e.g., "Increased diuretic dose may affect glucose control - monitoring Q4hrs"]
- [e.g., "New beta-blocker for CHF - may mask hypoglycemia symptoms"]

Shared Alerts:
- [e.g., "Dizziness: Glucose 3.2 mmol/L (hypoglycemia), BP 95/60 (borderline low)"]
- [e.g., "Action: Treated hypoglycemia, held morning lisinopril"]

Plan:
- Continue monitoring all conditions
- [Specific adjustments for each condition]
- [Note interactions and special considerations]
```

---

## References

- American Heart Association/American College of Cardiology Multimorbidity Statement
- GOLD COPD Guidelines: Comorbidities Section
- ADA Standards of Care: Cardiovascular Disease and Risk Management in Diabetes
- Barnett K, et al. Epidemiology of multimorbidity. Lancet. 2012.

---

**Clinical Note**: Patients with multiple comorbidities require integrated care approaches. Always consider interactions between conditions, medications, and monitoring parameters. When in doubt, consult specialists for complex comorbidity combinations. Document all conditions and their interactions clearly in care plans.
